LM Advisors’s SAB Biotherapeutics SABS Stock Holding History

LM Advisors’s Portfolio SABS Stock Details SABS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-362	Closed	-$2.49K	–	620
2023 Q4	$2.49K	Buy	+362	New	+$3.04K	﹤0.01%	646

Other funds holding SABS

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

LM Advisors's SABS Position: Q1 2024 in Review

LM Advisors sold out of SAB Biotherapeutics (SABS) in Q1 2024, closing a stake of 362 shares — an estimated $2.49K sold.

LM Advisors first reported a position in SABS in Q4 2023 and held it in 1 quarter. The position peaked at $2.49K in Q4 2023. 24 funds tracked by Wall St. Rank hold SABS as of Q1 2024.

LM Advisors reported no remaining SAB Biotherapeutics position as of Q1 2024 after selling out during the quarter.
LM Advisors sold 362 SAB Biotherapeutics shares in Q1 2024, an estimated $2.49K.
LM Advisors first reported a position in SAB Biotherapeutics in Q4 2023 and held it in 1 quarter.
LM Advisors's SAB Biotherapeutics position peaked at $2.49K in Q4 2023.
24 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q1 2024.

Based on LM Advisors's 13F filing for Q1 2024, filed 15 May 2024.